Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, posted on X:
“Results from OptiTROP-B01 out in Nature Medicine.
The TROP2-ADC sacituzumab tirumotecan improved PFS and OS in highly pretreated mTNBC, irrespective of Trop2 exp. Results similar to ASCENT. Approved in China, may soon also reach the west (4th topo1 ADC).”
“Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.”
Authors: Yongmei Yin, Ying Fan, Quchang Ouyang, Lihua Song, Xiaojia Wang, Wei Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, Yuee Teng, Xianjun Tang, Zhongsheng Tong, Zhengkui Sun, Junyou Ge, Xiaoping Jin, Yina Diao, Gesha Liu, Binghe Xu
